CUA and Pfizer Canada Award Clinical Fellowships in Incontinence

CUA and Pfizer Canada Award Clinical Fellowships in Incontinence 
Researchers Daniel Yanko, MD & Rahul Bansal, MBBS, MS, MCh are
recipients of inaugural fellowship program 
KIRKLAND, QUEBEC -- (Marketwired) -- 01/08/14 --  Two Canadian
researchers have been awarded the first-ever Canadian Urological
Association and Pfizer Canada Clinical Fellowship in Incontinence.
With this funding, Alberta's Dr. Daniel Yanko and Ontario's Dr. Rahul
Bansal will conduct new projects to improve support, education and
treatment for Canadian patients with incontinence.  
Paediatric Pilot Program  
McMaster University and University of Toronto researcher Rahul Bansal
has been awarded one of two grants under the program, for a project
that is focused on studying the impacts of providing more
comprehensive, supportive treatment options for pediatric urology
patients. In particular, Dr. Bansal's research will look at the
treatment outcomes on condition, emotional health and quality of life
for a group of children diagnosed with nonneurogenic lower urinary
tract dysfunction. The study will evaluate outcomes for children who
participate in a one-hour group interactive session, involving video
teaching that will be shared with families - compared to children who
receive standard individual urotherapy.  
"While the need is growing, there is very little research involving
the special needs of children who suffer from urological and
incontinence symptoms," explains Dr. Bansal. "To ensure successful
treatment, our hypothesis is that children may need a more engaging,
teaching-oriented approach and that doesn't always fit within the
traditional urology clinic appointment."  
Overactive Bladder Registry Study  
Dr. Daniel Yanko of Vesia (The Alberta Bladder Centre at the
University of Calgary) earned a grant for its innovative pilot study
to develop an anonymous, encrypted Registry of Overactive Bladder
patients. The voluntary registry will track patient outcomes from a
physical and quality of life perspective in the hopes that sharing
the information will help advance treatment and care.  
"Overactive bladder is more common as people age, and untreated, it
can have a negative impact on quality of life - and even, in some
cases, cause depression," explains Dr. Yanko. "At Vesia, we have a
multi-disciplinary treatment model that combines urology, family
medicine, nursing and physiotherapy all in one setting, so we hope
that tracking richer data about our patient's experiences and quality
of life, will help other researchers and physicians."  
About the CUA/Pfizer Canada Clinical Fellowship in Incontinence 
The Canadian Urological Association (CUA) and Pfizer Canada's
fellowship program was created to provide support and funding for
Canadian urological researchers. The fellowship is focused on
advancing urological research and improving care for patients with
incontinence. The partnership awards $120,000 per year in the form of
two grants.  
"The burden of urological disorders in Canada is growing. With these
two awarded projects, the CUA and Pfizer are taking another step to
ensure that Canadian urologists will continue to lead in terms of
scientific discoveries and innovation in urology and specifically,
the field of incontinence," says Dr. Ricardo Rendon, Chair of the
Scientific Council of the Canadian Urological Association Scholarship
Foundation (CUASF).  
"Pfizer understands that experiences and challenges with incontinence
differ from patient to patient," says Dr. Bernard Prigent,
Vice-President of Medical Affairs, Pfizer Canada Inc. "Programs such
as these will help improve the care and quality of life for people
living with this condition. We are proud to support continued
research and investment in this therapeutic area." 
A second year with two new fellowships will take place in 2014-2015
(total $120,000). For more information on how to apply for 2014
grants, eligible research proposals, review criteria, notification
dates and submission process please visit   
About Canadian Urological Association  
The Canadian Urological Association represents and provides a voice
for all Canadian urologists and fosters dedications of all members of
the profession toward ensuring the highest possible standard of
urologic care of Canadians.  
About Pfizer Canada  
Pfizer Canada Inc. is the Canadian operation of Pfizer Inc., one of
the world's leading biopharmaceutical companies. Our diversified
health care portfolio includes some of the world's best known and
most prescribed medicines and vaccines. Historically, Pfizer Inc. has
invested more than US$7 billion toward developing safe and effective
medicines. Pfizer Canada is a major contributor to Canadian R&D, with
investments totalling $89 million in 2012. To learn more about Pfizer
Canada, visit or you can follow us on Twitter
( or Facebook ( 
Catherine Millar
Canadian Urological Association 
Aidan Nguyen or Debra Quinn
Strategic Objectives
Toll free: 1-866-366-7733
Press spacebar to pause and continue. Press esc to stop.